WuXi Biologics (2269.HK), a China-based global Contract Research, Development and Manufacturing Organisation (CRDMO), announced on Wednesday that it has been recognised as a constituent company of the FTSE4Good Index Series.

This is the fourth consecutive year that the firm has been included in the Index for its outstanding sustainability performance.

The FTSE4Good Index Series is aimed at measuring the performance of companies demonstrating good sustainability practices. The companies are included in FTSE4Good Index Series based on independent evaluation of data from more than 8,000 securities in 47 developed and emerging countries.

Dr Chris Chen, WuXi Biologics CEO and chairman of the ESG Committee, said, 'We are very proud to be acknowledged again by FTSE Russell as a constituent of the FTSE4Good Index Series. It underscores our firm commitment to sustainability, demonstrating the success of our comprehensive ESG strategy and our effective implementation of ESG approaches. Moving forward, we will continue to regard sustainability as the cornerstone of business growth, delivering consistently strong performance for the common good of the global community.'